Cowen Downgrades Axovant Sciences (AXON) to Market Perform

Axovant Sciences (NASDAQ:AXON) was downgraded by Cowen from an “outperform” rating to a “market perform” rating in a research report issued on Friday.

A number of other analysts also recently issued reports on the stock. Chardan Capital raised shares of Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 price target on the stock in a report on Wednesday, January 10th. ValuEngine downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Jefferies Group downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a report on Thursday, December 21st. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Axovant Sciences in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $14.14.

Shares of Axovant Sciences (NASDAQ:AXON) traded down $0.18 during midday trading on Friday, reaching $2.09. 4,637,700 shares of the company were exchanged, compared to its average volume of 3,987,733. Axovant Sciences has a 12-month low of $2.06 and a 12-month high of $27.98. The stock has a market capitalization of $225.11 and a P/E ratio of -0.90. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94.

Axovant Sciences (NASDAQ:AXON) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.09). equities analysts predict that Axovant Sciences will post -2.17 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after purchasing an additional 355 shares in the last quarter. Legal & General Group Plc lifted its holdings in Axovant Sciences by 20.2% during the second quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 1,168 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Axovant Sciences by 38.5% during the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 2,789 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Axovant Sciences by 16.6% during the second quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 3,184 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Axovant Sciences by 10.0% in the second quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after buying an additional 4,800 shares during the last quarter. 96.93% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://ledgergazette.com/2018/01/15/cowen-downgrades-axovant-sciences-axon-to-market-perform.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply